blood test 88.
(photo credit: )
NIS 2.2b green plan heads to cabinet • By GLOBES CORRESPONDENT
The cabinet will
vote on a NIS 2.2 billion plan to reduce Israel’s greenhouse gas emissions by
20% by 2020 at its upcoming meeting on Sunday. NIS 539 million of the plan’s
cost will be budgeted in 2011-12.
The comprehensive plan includes
reducing household electricity consumption, support for investments to reduce
greenhouse gas emissions by industry, educational activities and public
relations, and support for initial installations of innovative Israeli
The Ministry of National Infrastructures; the Ministry of
Environmental Protection; the Ministry of Housing and Construction; the Ministry
of Transport; the Ministry of Industry, Trade and Labor; and the Ministry of
Finance will be responsible for the plan.Blood test company wins FDA
• By GLOBES CORRESPONDENT
The Tel Aviv-based blood test developer
RapiDx has received authorization of successful registration of its Rapid Ring
device with the US Food and Drug Administration (FDA). RapiDx is a portfolio
company of TechnoPlus Ventures Ltd. (TASE:TNPV).
TechnoPlus owns 5.73% of
issued share capital of RapiDx, and 11.32% on a fully diluted basis.
FDA registration allows RapiDx to sell Rapid Ring in the US, a product which
fits around the finger and allows quick and effective drawing of blood without
the need of a medical professional. The company says it reduces the pain of the
lancet, and is intended for single use.
Rapid Ring can be integrated with
various existing blood drawing systems, and can be an effective solution to the
problem of drawing enough blood from the patient’s finger.
said that RapiDx intends to turn to strategic organizations in the US
diagnostics market for the distribution and sale of Rapid Ring, and to continue
to develop other products.Acro Group buys J’lem Light Rail stake
Acro Group Ltd. has acquired the 17.5% stake of Polar
Investments Ltd. (TASE: PLR) in CityPass, the Jerusalem light rail franchisee,
for NIS 26 million.
The core businesses of Acro Group, a private company
owned by Arbov Investments Ltd. and Virometal Investments Ltd., are real estate
and infrastructure. The company’s real estate portfolio in Israel and Manhattan
is worth NIS 3 billion. In Israel, the company’s main projects include a
prestigious residential tower block at 17 Rothschild Boulevard in Tel Aviv, the
New Tel Aviv Towers, the Gymnasia Tower in Tel Aviv, and the Herzliya Business
Center. In Manhattan, the company owns the East 51 Street building and a luxury
hotel opposite Bryant Park between 5th and 6th Avenues.
of Polar Investment’s CityPass stake will boost Acro Group’s infrastructure
business. Hapoalim bids for Turkish bank Bank Hapoalim (TASE: POLI) offered to
buy Adabank, a bank in Turkey, according to a report by Bloomberg news
But according to the report, Hapoalim was the only bidder in the
tender. However, its bid of $42 million was less than half the $90 million
minimum price that Turkey was seeking. Turkish regulators will now discuss the
offer and decide whether to accept it or not. Options for Turkey include
reopening the bidding, or negotiating with Bank Hapoalim.
already owns Turkish financial institution Bank Pozitif, which does not have a
license to accept consumer deposits. Buying Adabank, which does have the
necessary license, would give Hapoalim the ability to collect
deposits.Dental implant co needs NIS 5-6m
• By GALI WEINREB
informed “Globes” that dental implant developer Sialo Technology Israel Ltd.
(TASE: SALO) is seeking to raise NIS 5-6 million, according to its
Sialo develops minimally invasive treatments for root canal
treatment, saliva stones, and dental implants. The treatments are based on the
company’s proprietary fiber optic endoscopes for direct viewing into the mouth
instead of current blind treatments.
Sialo’s share price rose 0.7%
yesterday to NIS 2.29, giving a market cap of NIS 36 million.Osem gains
in domestic market
• By KOBY YESHAYAHOU
Food producer Osem Investments Ltd.
(controlled by Nestle (SWX:NESN)) (TASE: OSEM) reported a rise of 11.9% in third
quarter revenue, reaching NIS 986.15 million, up from NIS 881.3 million in the
corresponding quarter of last year.
Sales in Israel over the first nine
months of the year rose 13.45% to NIS 2.35 billion, compared to NIS 2.08 billion
in the corresponding period of last year. The rise came from organic growth in
the company’s sales in Israel, as well as the acquisition of Materna which
contributed 9.9% to the gain in sales.
Profit rose 1.8% to NIS 90.76
million, compared to NIS 89.11 million in last year’s corresponding period.